Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group

Arthritis and Rheumatism

Volumn 63, Issue 10, 2011, Pages 3078-3085

  Khanna, Dinesh ^a   Tseng, Chi Hong ^a   Farmani, Niloofar ^b   Steen, Virginia ^c   Furst, Daniel E ^a   Clements, Philip J ^a   Roth, Michael D ^a   Goldin, Jonathan ^a   Elashoff, Robert ^a   Seibold, James R ^d   Saggar, Rajeev ^a   Tashkin, Donald P ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CENTROMERE ANTIBODY; CYCLOPHOSPHAMIDE; RNA ANTIBODY; RNA POLYMERASE III ANTIBODY; SCL 70 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC;

EID: 80053479089     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30467     Document Type: Article

References (19)

1. Steen VD, Medsger TA Jr,. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4. (Pubitemid 46999798)
2. Steen VD, Conte C, Owens GR, Medsger TA Jr,. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-9. (Pubitemid 24320744)
3. Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE,. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55: 598-602. (Pubitemid 44289880)
4. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54. (Pubitemid 351860934)
5. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
6. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, et al, for the Scleroderma Lung Study Group. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the Scleroderma Lung Study. Arthritis Rheum 2007; 56: 1676-84. (Pubitemid 46764099)
7. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al, for the Scleroderma Lung Study Group. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592-600. (Pubitemid 40216324)
8. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA,. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54. (Pubitemid 30397594)
9. Mahler DA, Weinberg DH, Wells CK, Feinstein AR,. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-8. (Pubitemid 14121920)
10. Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, et al, for the Scleroderma Lung Study Group. Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial-results from the Scleroderma Lung Study. Rheumatology (Oxford) 2009; 48: 1537-40.
11. MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720-35. (Pubitemid 41448672)
12. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511-22. (Pubitemid 41264217)
13. Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the Scleroderma Lung Study. Chest 2009; 136: 1333-40.
14. Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008; 134: 358-67.
15. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977-83. (Pubitemid 27406888)
16. Schettino IA, Ab'Saber AM, Vollmer R, Saldiva PH, Carvalho CR, Kairalla RA, et al. Accuracy of high resolution CT in assessing idiopathic pulmonary fibrosis histology by objective morphometric index. Pathol Res Pract 2002; 198: 347-54. (Pubitemid 34679104)
17. Antoniou KM, Wells AU,. Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol 2008; 20: 686-91.
18. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, et al, and the Scleroderma Lung Study Research Group. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177: 91-8.
19. Khanna D, Brown KK, Clements PJ, Elashoff R, Furst DE, Goldin J, et al. Systemic sclerosis-associated interstitial lung disease: proposed recommendations for future clinical trials. Clin Exp Rheumatol 2010; 28: S55-62.